Glassia FDA Approval History
FDA Approved: Yes (First approved July 1, 2010)
Trade names: Glassia
Generic name: alpha1-proteinase inhibitor (human)
Routes of administration: Injection
Previous Name: AAT-IV
Company: Kamada Ltd.
Target disease: Alpha-1 Proteinase Inhibitor Deficiency
Pregnancy Category: US: B (No risks have been found in humans.)
ATC code: B02AB02
Glassia is an alpha1-proteinase inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1antitrypsin deficiency.
Development timeline for Glassia
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.